HC Wainwright restated their neutral rating on shares of HilleVax (NASDAQ:HLVX – Free Report) in a report released on Monday, Benzinga reports. They currently have a $2.00 price target on the stock.
HLVX has been the subject of a number of other research reports. JPMorgan Chase & Co. reiterated a neutral rating and issued a $5.00 price objective (down previously from $24.00) on shares of HilleVax in a report on Monday, July 8th. SVB Leerink cut HilleVax from an outperform rating to a market perform rating and cut their price target for the company from $28.00 to $2.00 in a report on Tuesday, July 9th. Stifel Nicolaus lowered HilleVax from a buy rating to a hold rating and lowered their price objective for the stock from $34.00 to $3.00 in a research note on Tuesday, July 9th. Guggenheim downgraded HilleVax from a buy rating to a neutral rating in a research note on Monday, July 8th. Finally, Leerink Partnrs cut shares of HilleVax from a strong-buy rating to a hold rating in a research report on Tuesday, July 9th. Six equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has an average rating of Hold and an average target price of $9.20.
View Our Latest Report on HilleVax
HilleVax Stock Performance
HilleVax (NASDAQ:HLVX – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.10). As a group, equities research analysts expect that HilleVax will post -2.58 earnings per share for the current fiscal year.
Insider Buying and Selling at HilleVax
In other HilleVax news, Director Aditya Kohli sold 6,000 shares of HilleVax stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $14.73, for a total value of $88,380.00. Following the sale, the director now owns 764,878 shares in the company, valued at $11,266,652.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 71.10% of the company’s stock.
Institutional Investors Weigh In On HilleVax
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. EntryPoint Capital LLC purchased a new stake in HilleVax in the first quarter valued at $80,000. SG Americas Securities LLC purchased a new stake in shares of HilleVax in the 4th quarter valued at $139,000. Tidal Investments LLC purchased a new stake in shares of HilleVax in the 1st quarter valued at $207,000. abrdn plc purchased a new stake in shares of HilleVax in the 4th quarter valued at $433,000. Finally, Swiss National Bank raised its holdings in shares of HilleVax by 22.4% in the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after buying an additional 7,000 shares during the period. Hedge funds and other institutional investors own 86.42% of the company’s stock.
HilleVax Company Profile
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
See Also
- Five stocks we like better than HilleVax
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Brinker International’s Price Dip is an Appetizing Entry Point
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Stocks That Could Beat the September Blues
- Want to Profit on the Downtrend? Downtrends, Explained.
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.